The establishment of a Special Committee is a procedural step that increases the probability of a formal go-private process, but the lack of a price or definitive terms leaves significant uncertainty. Monitor for a definitive agreement filing (e.g., SC 13E3 or merger proxy) and any competing bids; the consortium's ability to secure financing and the Special Committee's evaluation of strategic alternatives will determine the outcome.
Price Chart
Executive Summary
111, Inc. announced the formation of a Special Committee of independent directors to evaluate a preliminary, non-binding going-private proposal from a consortium including co-founders and Huadeng Tech BioArray Ventures, dated September 16, 2026. This procedural step formalizes the board's review process for the take-private transaction, which would delist the company from Nasdaq. The filing itself is an administrative update with no new financial terms or definitive agreement, but the cross-filing context of the activist consortium agreement and the company's declining revenue profile (FY2025 -12.8%) heightens the significance of the go-private process.
Key Facts
- Special Committee established on September 28, 2026, comprising three independent directors: Jian Sun (chair), Nee Chuan Teo, and Jun Luo.
- Committee will evaluate the preliminary non-binding proposal dated September 16, 2026, from a consortium including co-founders and Huadeng Tech BioArray Ventures.
- The proposal contemplates acquiring all Class A ordinary shares not already owned by the consortium and delisting from Nasdaq.
- No definitive agreement has been reached; the board cautions that no decisions have been made and there is no assurance a transaction will occur.
- Cross-filing context: A consortium agreement (SC 13D filed Sept 17, 2026) details the consortium structure and negotiation framework, and the FY2025 20-F reported a 12.8% revenue decline to RMB12.6 billion.
Financial Impact
No financial terms disclosed in this filing; the preliminary proposal amount is undisclosed.
Risk Factors
- The proposal is preliminary and non-binding; no assurance of a definitive agreement or consummation.
- The company's declining revenue (FY2025 -12.8%) and overhang from redeemable non-controlling interests (RMB1.1 billion) could complicate valuation and financing.
- Potential for competing bids or shareholder opposition to the proposed price.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0000950103-26-014553 |
| Document: dp253899_6k.htm | 0000950103-26-014553 |
| Document: 0000950103-26-014553-index-headers.html | 0000950103-26-014553 |
| Document: 0000950103-26-014553-index.html | 0000950103-26-014553 |
| Document: 0000950103-26-014553.txt | 0000950103-26-014553 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $2.86 | awaiting T+60 | — | $3.00 (+4.90%) |
Sep 28, 2026 29d ago | 6-K | $3.52 | awaiting T+60 | — | $3.00 (−14.77%) |
Sep 17, 2026 5w ago | SC 13D | $3.54 | awaiting T+60 | — | $3.00 (−15.25%) |
Sep 17, 2026 5w ago | 6-K | $3.54 | awaiting T+60 | — | $3.00 (+15.25%) |
Sep 17, 2026 5w ago | 6-K | $3.54 | awaiting T+60 | — | $3.00 (−15.25%) |
Sep 17, 2026 5w ago | Press Release | $3.54 | awaiting T+60 | — | $3.00 (−15.25%) |
Jun 16, 2026 19w ago | Insider Cluster | $4.45 $3.45 | ▼ −22.47% | ▼ −23.47% | $3.00 (−32.58%) |
Jun 12, 2026 19w ago | Insider Cluster | $4.89 $3.20 | ▲ +34.56% | ▲ +37.82% | $3.00 (+38.65%) |
Jun 4, 2026 20w ago | 6-K | $4.72 $3.46 | ▲ +26.69% | ▲ +28.58% | $3.00 (+36.44%) |
May 29, 2026 21w ago | Insider Cluster | $5.28 $3.53 | ▼ −33.14% | ▼ −34.33% | $3.00 (−43.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers